. Anonyme, Naltrexone : une effet transitoire sur l'abstinence alcoolique, La Revue Prescrire, vol.18, issue.186, pp.483-488, 1998.

R. Bartus, D. Emmerich, J. Hotz, M. Blaustein, R. Dean et al., Vivitrex??, an Injectable, Extended-Release Formulation of Naltrexone, Provides Pharmacokinetic and Pharmacodynamic Evidence of Efficacy for 1 Month in Rats, Neuropsychopharmacology, vol.28, issue.11, pp.1973-82, 2003.
DOI : 10.1038/sj.npp.1300274

P. Batel, Sevrage en milieu hospitalier, Rev Prat, vol.49, issue.4, pp.387-90, 1999.

D. A. Fiellin, P. G. O-'connor, H. E. Horwitz, and R. I. , Risk for Delirium Tremens in Patients With Alcohol Withdrawal Syndrome, Substance Abuse, vol.23, issue.2, pp.83-94, 2002.

V. Fourestié, Le syndrome de sevrage d'alcool est une urgence dont le traitement a évolué, Rev Prat, vol.12, issue.431, pp.9-12, 1998.

J. Froehlich, N. Badia?elder, and R. Zink, Contribution of the opioid system to alcohol aversion and alcohol drinking behavior, J Pharmacol Exp Ther, vol.287, pp.284-92, 1998.

P. Gache, Repérage et diagnostic des malades de l'alcool, Rev Prat, vol.49, issue.4, pp.375-78, 1999.

J. Garcia?monco and M. Beldarrain, Patients with alcohol problems, New Engl J Med, vol.339, p.130, 1998.

D. Huas and F. Pessionne, Les consommateurs d'alcool à problèmes, La Revue du Praticien, vol.49, issue.4, pp.379-82, 1999.

B. Johnson, Oral topiramate for treatment of alcohol dependence: a randomised controlled trial, The Lancet, vol.361, issue.9370, pp.1677-1685, 2003.
DOI : 10.1016/S0140-6736(03)13370-3

A. Manus, Alcoolisme : complications psychiatriques aiguës et chroniques, Rev Prat, vol.44, issue.18, pp.421-425, 1994.

G. Martinotti, D. Nicola, M. Janiri, and L. , Efficacy and Safety of Aripiprazole in Alcohol Dependence, The American Journal of Drug and Alcohol Abuse, vol.113, issue.2, pp.393-401, 2007.
DOI : 10.1016/0021-9681(81)90058-8

O. Connor and R. Schottenfeld, Patients with Alcohol Problems, New England Journal of Medicine, vol.338, issue.9, pp.592-602, 1998.
DOI : 10.1056/NEJM199802263380907

. Anonyme, Dysphagie due aux benzodiazépines, La Revue Prescrire, vol.19, pp.123-127, 0192.

. Anonyme, Polytoxicomanie et traitement de substitution Usage et mésusage des benzodiazépines chez les usagers de drogues (1ère partie), Act. Med. Int. Psychiatrie, vol.203, issue.14, pp.3476-3483, 1997.

. Anonyme, Polytoxicomanie et traitement de substitution Usage et mésusage des benzodiazépines chez les toxicomanes (2ème partie), Act. Med. Int. Psychiatrie, vol.203, issue.14, pp.3476-3483, 1997.

D. Bobon, Les bases biologiques de la pharmacodépendance : les benzodiazépines, Rev Med Liege, vol.61, issue.5, pp.165-73, 1986.

M. Fatséas, E. Lavie, C. Denis, P. Franques-rénéric, J. Tignol et al., Sevrage aux benzodiaz??pines des sujets d??pendants aux opiac??s en traitement de substitution, La Presse M??dicale, vol.35, issue.4, pp.599-606, 2006.
DOI : 10.1016/S0755-4982(06)74647-4

P. Parquet, D. Bailly, and D. Servant, Les médicaments du sevrage des toxicomanies, Psychol Med, vol.21, issue.13, pp.2012-2018, 1989.

A. Pelissolo and J. Bisserbe, Dépendance aux benzodiazépines. Aspects cliniques et biologiques, Encephale, pp.147-57, 1994.

D. Quinn, A. Wodak, and R. Day, Pharmacokinetic and Pharmacodynamic Principles of Illicit Drug Use and Treatment of Illicit Drug Users, Clinical Pharmacokinetics, vol.33, issue.5, pp.344-400, 1997.
DOI : 10.2165/00003088-199733050-00003

M. Reynaud, D. Elloy?giraud, E. Turbe, S. Chassaing, J. Coudert et al., Benzodiazépines : consommation au long cours et toxicomanie. Profil des consommateurs en milieu psychiatrique, Psychotropes, vol.7, issue.2, pp.55-65, 1992.

C. Gyllenhaal, S. L. Merritt, S. D. Peterson, K. I. Block, and T. Gochenour, Efficacy and safety of herbal stimulants and sedatives in sleep disorders, Sleep Medicine Reviews, vol.4, issue.3, pp.229-251, 2000.
DOI : 10.1053/smrv.1999.0093

W. C. Lafrance, The Use of Herbal Alternative Medicines in Neuropsychiatry, The Journal of Neuropsychiatry and Clinical Neurosciences, vol.12, issue.2, pp.177-192, 2000.
DOI : 10.1176/jnp.12.2.177

Y. Meng, M. Dukat, and D. Bridgen, Pharmacological effects of methamphetamine and other stimulants via inhalation exposure, Drug and Alcohol Dependence, vol.53, issue.2, pp.111-120, 1999.
DOI : 10.1016/S0376-8716(98)00120-3

A. Oro and S. Dixon, Perinatal Cocaine and Methamphetamine Exposure, Obstetrical & Gynecological Survey, vol.43, issue.7, pp.571-579, 1987.
DOI : 10.1097/00006254-198807000-00011

M. Benson and A. Bentley, Lung disease induced by drug addiction., Thorax, vol.50, issue.11, pp.1125-1132, 1995.
DOI : 10.1136/thx.50.11.1125

C. Clemessy and F. Baud, Intoxication aiguë par les opiacés, la cocaïne et l'ecstasy, Le Concours Medical, vol.120, issue.01, pp.24-31, 1998.

L. Cregler and M. Herbert, Medical Complications of Cocaine Abuse, New England Journal of Medicine, vol.315, issue.23, pp.1495-1500, 1986.
DOI : 10.1056/NEJM198612043152327

V. Delanay?black, C. Covington, T. Templin, J. Ager, S. Martier et al., Prenatal Cocaine Exposure and Child Behavior, PEDIATRICS, vol.102, issue.4, pp.945-50, 1998.
DOI : 10.1542/peds.102.4.945

B. Fox, Development of a therapeutic vaccine for the treatment of cocaine addiction, Drug and Alcohol Dependence, vol.48, issue.3
DOI : 10.1016/S0376-8716(97)00121-X

D. Gorelick, Enhancing cocaine metabolism with butyrylcholinesterase as a treatment strategy, Drug and Alcohol Dependence, vol.48, issue.3, pp.159-65, 1997.
DOI : 10.1016/S0376-8716(97)00119-1

M. Kaufman, J. Levin, and M. Ross, Cocaine-Induced Cerebral Vasoconstriction Detected in Humans With Magnetic Resonance Angiography, JAMA, vol.279, issue.5, pp.376-380, 1998.
DOI : 10.1001/jama.279.5.376

P. Marzuk, K. Tardiff, and A. Leon, Ambient Temperature and Mortality From Unintentional Cocaine Overdose, JAMA, vol.279, issue.22, pp.1795-1800, 1998.
DOI : 10.1001/jama.279.22.1795

P. T. Morgan, E. F. Pace-schott, S. Z. Coric, V. Stickgold, R. Malison et al., Sleep, sleep-dependent procedural learning and vigilance in chronic cocaine users: Evidence for occult insomnia, Drug and Alcohol Dependence, vol.82, issue.3, pp.238-249, 2006.
DOI : 10.1016/j.drugalcdep.2005.09.014

D. Quinn, A. Wodak, and R. Day, Pharmacokinetic and Pharmacodynamic Principles of Illicit Drug Use and Treatment of Illicit Drug Users, Clinical Pharmacokinetics, vol.33, issue.5, pp.344-400, 1997.
DOI : 10.2165/00003088-199733050-00003

J. Schlatter, G. Nester, and A. Trylesinski, Le crack : une forme de cocaïne inhale, Presse Med, vol.26, pp.1695-1698, 1997.

J. A. Schroeder, M. Hummel, A. D. Simpson, R. Sheikh, S. A. Unterwald et al., A role for mu opioid receptors in cocaine-induced activity, sensitization, and reward in the rat, Psychopharmacology, vol.2, issue.1, pp.265-272, 2007.
DOI : 10.1007/s00213-007-0883-z

M. Sofuoglu, S. Dudish-poulsen, S. B. Brown, and D. K. Hatsukami, Association of cocaine withdrawal symptoms with more severe dependence and enhanced subjective response to cocaine, Drug and Alcohol Dependence, vol.69, issue.3, pp.273-282, 2003.
DOI : 10.1016/S0376-8716(02)00328-9

S. Sparenberg, F. Vocci, and S. Zukin, Peripheral cocaine?blocking agents: new medication for Métabolisation hépatique 90%

N. Benowitz, Treating Tobacco Addiction ??? Nicotine or No Nicotine?, New England Journal of Medicine, vol.337, issue.17, pp.1230-1231, 1997.
DOI : 10.1056/NEJM199710233371710

R. Caraballo, G. Giovino, and T. Pechacek, Racial and Ethnic Differences in Serum Cotinine Levels of Cigarette Smokers, JAMA, vol.280, issue.2, pp.135-141, 1998.
DOI : 10.1001/jama.280.2.135

R. Jones, Tobacco dependence In : Psychopharmacology : the thrid generation of progress, 1987.

G. Mathern, C. Perrier, B. J. Lagrue, and G. , L'utilisation du tabac à chiquer, Une pratique émergente chez les adolescents, Presse Med, vol.34, pp.1145-1146, 2005.

A. Ott, Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam Study, The Lancet, vol.351, issue.9119, pp.1840-1843, 1998.
DOI : 10.1016/S0140-6736(97)07541-7

D. Quinn, A. Wodak, and R. Day, Pharmacokinetic and Pharmacodynamic Principles of Illicit Drug Use and Treatment of Illicit Drug Users, Clinical Pharmacokinetics, vol.33, issue.5, pp.344-400, 1997.
DOI : 10.2165/00003088-199733050-00003

C. Uelingher, Approche cognitivo?comportementale du traitemetn de l'alcoolodépendance, Rev Prat, vol.49, pp.395-404, 1999.

M. Galliot?guilley, C. Sueur, and B. Lebeau, L'ecstasy et ses sosies, Presse Med, vol.285, issue.7, pp.358-62, 1997.

J. Henry, J. Fallon, and A. Kicman, Low-dose MDMA (???ecstasy???) induces vasopressin secretion, The Lancet, vol.351, issue.9118, p.1784, 1998.
DOI : 10.1016/S0140-6736(05)78744-4

E. J. Jaehne, A. Salem, and R. J. Irvine, Effects of 3,4-methylenedioxymethamphetamine and related amphetamines on autonomic and behavioral thermoregulation, Pharmacology Biochemistry and Behavior, vol.81, issue.3
DOI : 10.1016/j.pbb.2005.04.005

E. J. Jaehne, A. Salem, and R. J. Irvine, Pharmacological and behavioral determinants of cocaine, methamphetamine, 3,4-methylenedioxymethamphetamine, and para-methoxyamphetamine-induced hyperthermia, Psychopharmacology, vol.20, issue.1, pp.41-52, 2007.
DOI : 10.1007/s00213-007-0825-9

K. Jansen, Ecstasy (MDMA) dependence, Drug and Alcohol Dependence, vol.53, issue.2, pp.121-124, 1999.
DOI : 10.1016/S0376-8716(98)00111-2

F. Lapostolle, C. Eliez, E. Massioui, and Y. , Toxicité de l'ecstasy, Presse Med, vol.26, issue.38, pp.1881-1885, 1997.

F. Nagai, R. Nonaka, and K. S. Kamimura, The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain, European Journal of Pharmacology, vol.559, issue.2-3, pp.132-137, 2007.
DOI : 10.1016/j.ejphar.2006.11.075

R. J. , H. D. , F. P. , T. M. Cunningham, and K. A. , Chronic treatment with a serotonin2 receptor (5-HT2R) agonist modulates the behavioral and cellular response to (+)-3,4-methylenedioxymethamphetamine, Drug and Alcohol Dependence, vol.81, pp.117-127, 2006.

J. Salzmann, C. Marie-claire, and F. Noble, Effets aigus et ?? long terme de l???ecstasy, La Presse M??dicale, vol.33, issue.18, pp.24-32, 2004.
DOI : 10.1016/S0755-4982(04)72379-9

F. Schifano, A bitter pill. Overview of ecstasy

A. Bibliographie, Communiqué de presse : Classement comme stupéfiant de la BZP, 2008.

P. Gee, S. Richardson, W. Woltersdorf, and G. Moore, Toxic effects of BZP-based herbal party pills in humans: a prospective study in Christchurch, NZMJ, vol.118, pp.1-10, 1227.

?. Europol and . Emcdda, Joint Report on a new psychoactive substance: 1-benzylpiperazine (BZP), 2007.

A. H. Ewald and H. Maurer, H2,5-Dimethoxyamphetamine-derived designer drugs: Studies on the identification of cytochrome P450 (CYP) isoenzymes involved in formation of their main metabolites and on their capability to inhibit CYP2D6, Toxicol Lett, 2008.

S. Astley and R. Little, Maternal marijuana use during lactation and infant development at one year, Neurotoxicology and Teratology, vol.12, issue.2, pp.161-169, 1990.
DOI : 10.1016/0892-0362(90)90129-Z

A. J. Budney, N. P. , and H. J. , Marijuana withdrawal among adults seeking treatment for marijuana dependence, Addiction, vol.94, issue.9, pp.1311-1321, 1999.
DOI : 10.1046/j.1360-0443.1999.94913114.x

J. Costentin, Données neurobiologiques récentes sur le cannabis, Bull Acad Nat Med, vol.186, issue.2, pp.319-329, 2002.

J. Costentin, Neuropsychopharmacologie du delta-9-t??trahydrocannabinol (THC), Annales Pharmaceutiques Fran??aises, vol.66, issue.4, pp.219-231, 2008.
DOI : 10.1016/j.pharma.2008.07.003

J. Costentin, Nouveau regard sur le cannabis URL : http://www.univrouen .fr/servlet/com.univ.utils.LectureFichierJoint?, pp.1106311066808-0, 2005.

M. Diana, M. Melis, A. Muntoni, and G. Gessa, Mesolimbic dopaminergic decline after cannabinoid withdrawal, Proceedings of the National Academy of Sciences, vol.95, issue.17, pp.10269-73, 1999.
DOI : 10.1073/pnas.95.17.10269

W. Hall and N. Solavij, Adverse effects of cannabis, The Lancet, vol.352, issue.9140, pp.1611-1627, 1998.
DOI : 10.1016/S0140-6736(98)05021-1

M. Haney, A. Ward, S. Comer, R. Foltin, and M. Fishman, Abstinence symptoms following smoked marijuana in humans, Psychopharmacology, vol.141, issue.4, pp.395-404, 1999.
DOI : 10.1007/s002130050849

F. Holsten, Flashbacks: A personal follow-up, Archiv f???r Psychiatrie und Nervenkrankheiten, vol.92, issue.6, pp.293-304, 1976.
DOI : 10.1007/BF00343238

X. Kyndt, P. Ducq, and D. Reumaux, Artérite du cannabis versus maladie de Léo Buerger, Presse Med, vol.28, issue.2, pp.71-75, 1999.

X. Laqueille, C. Launay, and M. Kanit, Les troubles psychiatriques et somatiques induits par le cannabis, Annales Pharmaceutiques Fran??aises, vol.66, issue.4, pp.245-254, 2008.
DOI : 10.1016/j.pharma.2008.06.001

M. Reynaud, Addictions et psychiatrie, 2005.

M. B. Budney and A. J. , Relapse in outpatient treatment for marijuana dependence

P. Mura, B. Brunet, F. Favreau, and T. Hauet, Cannabis et accidents de la voie publique : r??sultats des derni??res ??tudes fran??aises, Annales Pharmaceutiques Fran??aises, vol.64, issue.3, pp.192-196, 2006.
DOI : 10.1016/S0003-4509(06)75312-3

D. Piomelli, The endogenous cannabinoid system and the treatment of marijuana dependence, Neuropharmacology, vol.47, pp.359-367, 2004.
DOI : 10.1016/j.neuropharm.2004.07.018

M. Stanton, J. Mintz, and R. Franklin, Drug flashbacks II Some additionnal findings, International Journal, vol.11, issue.1, pp.53-69, 1976.
DOI : 10.3109/10826087109045530

S. Wieviorka, Aspects médico?psychologiques de la consommation de cannabis, Rev Prat, vol.45, pp.1367-70, 1995.

J. Yager, E. Crumpton, and R. Rubenstein, Flashbacks among soldiers discharged as unfit who abused more than one drug, Am J Psychiatry, vol.140, issue.7, pp.857-61, 1983.

C. Dextrométhorphane, Candy -Dex -DM -DXM -Poor man's PCP -Red Devil -Robo -Rojo -Skittles -Triple C's -Tussin ? Velvet

. Vomissements, sueurs nocturnes, myalgies, diarrhée, sensation de froid, agitation

R. Allen, A. Granger, and L. Dykstra, Dextromethorphan Potentiates the Antinociceptive Effects of Morphine and the delta -Opioid Agonist SNC80 in Squirrel Monkeys, Journal of Pharmacology and Experimental Therapeutics, vol.300, issue.2, pp.435-441, 2002.
DOI : 10.1124/jpet.300.2.435

P. A. Chyka, Dextromethorphan poisoning: An evidence-based consensus guideline for out-of-hospital management, Clinical Toxicology, vol.319, issue.6, pp.662-677, 2007.
DOI : 10.1097/00004583-199912000-00004

J. Cornish, A randomized, double-blind, placebo-controlled safety study of high-dose dextromethorphan in methadone-maintained male inpatients, Drug and Alcohol Dependence, vol.67, issue.2, pp.177-183, 2002.
DOI : 10.1016/S0376-8716(02)00025-X

M. Gavend, M. Mallaret, M. Dematteis, and G. Baragatti, Discriminative stimulus properties of dextromethorphan in rats, Biomedicine & Pharmacotherapy, vol.49, issue.10, pp.456-64, 1995.
DOI : 10.1016/0753-3322(96)82690-4

M. Henderson and R. Fuller, Dextromethorphan antagonizes the acute depletion of brain serotonin by p-chloroamphetamine and H75/12 in rats, Brain Research, vol.594, issue.2, pp.323-329, 1992.
DOI : 10.1016/0006-8993(92)91144-4

S. Holtzman, Discriminative stimulus effects of dextromethorphan in the rat, Psychopharmacology, vol.206, issue.3
DOI : 10.1007/BF02245325

J. H. Jun, T. E. Schindler, and C. W. , Abuse liability and stimulant properties of dextromethorphan and diphenhydramine combinations in rats, Psychopharmacology, vol.172, pp.277-282, 2004.

K. Luk, T. Kennedy, and A. Sadikot, Glutamate promotes proliferation of striatal neuronal progenitors by an NMDA receptor?mediated mechanism, J Neurosci, vol.23, issue.6, pp.2239-50, 2003.

S. C. Miller, Dextromethorphan psychosis, dependence and physical withdrawal, Addiction Biology, vol.15, issue.4, pp.325-327, 2005.
DOI : 10.1080/13556210500352410

L. Zawertilo, H. Kaplan, U. Busto, R. Tyndale, and E. Sellers, Psychotropic Effects of Dextromethorphan Are Altered by the CYP2D6 Polymorphism, Journal of Clinical Psychopharmacology, vol.18, issue.4, pp.332-339, 1998.
DOI : 10.1097/00004714-199808000-00014

V. Ziaee, Side effects of dextromethorphan abuse, a case series, Addictive Behaviors, vol.30, issue.8, pp.1607-1613, 2005.
DOI : 10.1016/j.addbeh.2005.02.005

E. Heiligenstein and G. Guenther, Over the counter psychotropics: a review of melatonin

W. H. Richardson, C. M. Slone, and J. E. Michels, Herbal Drugs of Abuse: An Emerging Problem, Emergency Medicine Clinics of North America, vol.25, issue.2, pp.435-457, 2005.
DOI : 10.1016/j.emc.2007.02.009

&. Acide-barrels-bevis and D. Butthead-big, Blue acid - California sunshine -Chief -Cubes -D -Dome -Face melter -Flats - Frogs -Ghost -Green caps -Hawks -Hawaiian baby woodrose -Heavenly blue -Instant zen -La Souris Déglinguée -Lids -SD 25 -Lucy in the Sky with Diamonds -Microdot -Morning Glory -Orange wedges -Paper acid -Pearly gates -Pink drops -Purples wedges -Purpule haze -Royal blue -Sunshine -Wedding bells -Wedges -Window pane

L. Le, que l'on retrouve dans la nature dans les graines d'Ipomoea violacea (Morning Glory)

. Le-potentiel-d, abus existe, mais il est difficile d'évaluer le potentiel de dépendance du fait de la tolérance élevée

P. Par-voie-orale, et parfois sniffé ou injecté en transcutanée. Surtout adolescents et jeunes adultes lors des fins de semaine

H. Abraham and A. Mamen, LSD-Like Panic From Risperidone in Post-LSD Visual Disorder, Journal of Clinical Psychopharmacology, vol.16, issue.3, pp.238-279, 1996.
DOI : 10.1097/00004714-199606000-00008

V. Watts, C. Lawler, and D. Fox, LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors, Psychopharmacology, vol.22, issue.4, pp.401-410, 1995.
DOI : 10.1007/BF02245940

W. H. Richardson, C. M. Slone, and J. E. Michels, Herbal Drugs of Abuse: An Emerging Problem, Emergency Medicine Clinics of North America, vol.25, issue.2, pp.435-457, 2005.
DOI : 10.1016/j.emc.2007.02.009

P. Salvinorine, A. , B. , C. , and D. , diterpènes agonistes des récepteurs kappa opioïdes, Salvinorine A : la plus psychoactive, agoniste hautement sélectif des récepteurs kappa opioïdes qui serait équipotent à la dynorphine A, l'agoniste endogène, Seul hallucinogène non alcaloïde connu. Ce composé est le plus puissant hallucinogène naturel isolé à ce jour

. Pas-de-cas-de-dépendance-décrit-dans-la-littérature, Une étude a démontré une faible aversion pour les effets de salvinorine A chez les animaux, ce qui suggère que le complexe n'induirait pas de dépendance. Toutefois, aucun rapport n'existe actuellement dans la littérature sur la tolérance

@. Feuilles-fumées, La salvinorine A est efficace à des doses de 200-500 µg et produit des effets rapides et intenses en 5 à 6 min et qui durent 20 à 30 minutes, Alors que des doses de plus de 2 mg sont efficaces pour beaucoup plus longtemps

K. M. Babu, C. R. Mccurdy, and E. W. Boyer, and Kratom, Clinical Toxicology, vol.198, issue.1, pp.146-152, 2008.
DOI : 10.1248/cpb.52.916

D. Braida, Hallucinatory and rewarding effect of salvinorin A in zebrafish: ??-opioid and CB1-cannabinoid receptor involvement, Psychopharmacology, vol.4, issue.4, pp.441-448, 2007.
DOI : 10.1007/s00213-006-0639-1

M. Imanshahidi and H. Et-hosseinzadeh, The pharmacological effects ofSalvia species on the central nervous system, Phytotherapy Research, vol.24, issue.6, pp.427-437, 2006.
DOI : 10.1002/ptr.1898

J. T. , F. L. Erlichman, and J. S. , The antinociceptive effect of Salvinorin A in mice, European Journal of Pharmacology, vol.545, pp.129-133, 2006.

J. E. Lange, College student use of Salvia divinorum, Drug and Alcohol Dependence, vol.94, issue.1-3, pp.263-266, 2008.
DOI : 10.1016/j.drugalcdep.2007.10.018

I. Ofdt-site, Note d'information du 19 juillet Première identification du principe actif de la Salvia Divinorum dans SINTES, 2002.

S. Singh, Adolescent salvia substance abuse, Addiction, vol.43, issue.5, pp.823-824, 2007.
DOI : 10.1111/j.1360-0443.2007.01810.x

. Hoover, Internet access to Salvia divinorum: Implications for policy, prevention, and treatment, Journal of Substance Abuse Treatment, vol.35, issue.1, pp.22-27, 2007.
DOI : 10.1016/j.jsat.2007.07.011

T. A. Vortherms and R. B. , Salvinorin A: From Natural Product to Human Therapeutics, Molecular Interventions, vol.6, issue.5, pp.257-265, 2006.
DOI : 10.1124/mi.6.5.7

C. B. Willmore-fordham, K. D. Mccurdy, C. R. Kinder, and D. H. , The hallucinogen derived from Salvia divinorum, salvinorin A, has ??-opioid agonist discriminative stimulus effects in rats, Neuropharmacology, vol.53, issue.4, pp.481-486, 2007.
DOI : 10.1016/j.neuropharm.2007.06.008